Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?

ABSTRACT We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Paul L. Fidel, Mairi C. Noverr
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2020
Materias:	MMR clinical trial inflammation COVID-19 live attenuated vaccines myeloid-derived suppressor cells Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/4602dabb073e400e80db6b5d611fbcd0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4602dabb073e400e80db6b5d611fbcd0
record_format	dspace
spelling	oai:doaj.org-article:4602dabb073e400e80db6b5d611fbcd02021-11-15T15:56:46ZCould an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?10.1128/mBio.00907-202150-7511https://doaj.org/article/4602dabb073e400e80db6b5d611fbcd02020-06-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.00907-20https://doaj.org/toc/2150-7511ABSTRACT We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing “trained” nonspecific innate immune cells for improved host responses against subsequent infections. Mortality in COVID-19 cases is strongly associated with progressive lung inflammation and eventual sepsis. Vaccination with MMR in immunocompetent individuals has no contraindications and may be especially effective for health care workers who can easily be exposed to COVID-19. Following the lead of other countries conducting clinical trials with the live attenuated Mycobacterium bovis BCG (BCG) vaccine under a similar concept, a clinical trial with MMR in high-risk populations may provide a “low-risk–high-reward” preventive measure in saving lives during this unprecedented COVID-19 pandemic.Paul L. FidelMairi C. NoverrAmerican Society for MicrobiologyarticleMMRclinical trialinflammationCOVID-19live attenuated vaccinesmyeloid-derived suppressor cellsMicrobiologyQR1-502ENmBio, Vol 11, Iss 3 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	MMR clinical trial inflammation COVID-19 live attenuated vaccines myeloid-derived suppressor cells Microbiology QR1-502
spellingShingle	MMR clinical trial inflammation COVID-19 live attenuated vaccines myeloid-derived suppressor cells Microbiology QR1-502 Paul L. Fidel Mairi C. Noverr Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
description	ABSTRACT We propose the concept that administration of an unrelated live attenuated vaccine, such as MMR (measles, mumps, rubella), could serve as a preventive measure against the worst sequelae of coronavirus disease 2019 (COVID-19). There is mounting evidence that live attenuated vaccines provide nonspecific protection against lethal infections unrelated to the target pathogen of the vaccine by inducing “trained” nonspecific innate immune cells for improved host responses against subsequent infections. Mortality in COVID-19 cases is strongly associated with progressive lung inflammation and eventual sepsis. Vaccination with MMR in immunocompetent individuals has no contraindications and may be especially effective for health care workers who can easily be exposed to COVID-19. Following the lead of other countries conducting clinical trials with the live attenuated Mycobacterium bovis BCG (BCG) vaccine under a similar concept, a clinical trial with MMR in high-risk populations may provide a “low-risk–high-reward” preventive measure in saving lives during this unprecedented COVID-19 pandemic.
format	article
author	Paul L. Fidel Mairi C. Noverr
author_facet	Paul L. Fidel Mairi C. Noverr
author_sort	Paul L. Fidel
title	Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
title_short	Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
title_full	Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
title_fullStr	Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
title_full_unstemmed	Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?
title_sort	could an unrelated live attenuated vaccine serve as a preventive measure to dampen septic inflammation associated with covid-19 infection?
publisher	American Society for Microbiology
publishDate	2020
url	https://doaj.org/article/4602dabb073e400e80db6b5d611fbcd0
work_keys_str_mv	AT paullfidel couldanunrelatedliveattenuatedvaccineserveasapreventivemeasuretodampensepticinflammationassociatedwithcovid19infection AT mairicnoverr couldanunrelatedliveattenuatedvaccineserveasapreventivemeasuretodampensepticinflammationassociatedwithcovid19infection
_version_	1718427085256523776

Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure To Dampen Septic Inflammation Associated with COVID-19 Infection?

Ejemplares similares